5124-25-4 Usage
Uses
Used in Textile Industry:
Disperse Yellow Se-Fl is used as a dye for polyester fiber dyeing and printing. It provides excellent fastness properties, making it a preferred choice for various textile applications.
The dye exhibits the following fastness ratings according to the American Association of Textile Chemists and Colorists (AATCC) standards:
1. Ironing Fastness: 5
2. Light Fastness: 5
3. Perspiration Fastness: 5
4. Washing Fastness (Fading): 5
5. Washing Fastness (Staining): 5
These ratings indicate that Disperse Yellow Se-Fl offers high resistance to fading and staining under various conditions, making it suitable for use in the production of durable and long-lasting textiles.
Preparation
2-Nitro-N-isobutylbenzenesulfonamide and Aniline condensation
Flammability and Explosibility
Notclassified
Standard
Ironing Fastness
Fading
Stain
Check Digit Verification of cas no
The CAS Registry Mumber 5124-25-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,1,2 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 5124-25:
(6*5)+(5*1)+(4*2)+(3*4)+(2*2)+(1*5)=64
64 % 10 = 4
So 5124-25-4 is a valid CAS Registry Number.
InChI:InChI=1/C18H15N3O4S/c22-21(23)18-13-16(26(24,25)20-15-9-5-2-6-10-15)11-12-17(18)19-14-7-3-1-4-8-14/h1-13,19-20H
5124-25-4Relevant academic research and scientific papers
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 189; 190, (2014/05/07)
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
